Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Intangibles: 2013-2023

Historic Intangibles for ImmunityBio (IBRX) over the last 10 years, with Dec 2023 value amounting to $17.1 million.

  • ImmunityBio's Intangibles fell 15.45% to $16.1 million in Q2 2024 from the same period last year, while for Jun 2024 it was $16.1 million, marking a year-over-year decrease of 15.45%. This contributed to the annual value of $17.1 million for FY2023, which is 14.55% down from last year.
  • As of FY2023, ImmunityBio's Intangibles stood at $17.1 million, which was down 14.55% from $20.0 million recorded in FY2022.
  • ImmunityBio's Intangibles' 5-year high stood at $20.0 million during FY2022, with a 5-year trough of $1.4 million in FY2021.
  • Over the past 3 years, ImmunityBio's median Intangibles value was $17.1 million (recorded in 2023), while the average stood at $12.8 million.
  • As far as peak fluctuations go, ImmunityBio's Intangibles soared by 1,308.66% in 2022, and later fell by 14.55% in 2023.
  • Over the past 4 years, ImmunityBio's Intangibles (Yearly) stood at $1.5 million in 2020, then decreased by 2.94% to $1.4 million in 2021, then skyrocketed by 1,308.66% to $20.0 million in 2022, then declined by 14.55% to $17.1 million in 2023.